Compare · BKHA vs GILD
BKHA vs GILD
Side-by-side comparison of Black Hawk Acquisition Corporation (BKHA) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BKHA and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD carries a market cap of $161.66B.
- Over the past year, BKHA is up 13.8% and GILD is up 13.5% - BKHA leads by 0.3 points.
- GILD has been more active in the news (6 items in the past 4 weeks vs 3 for BKHA).
- GILD has more recent analyst coverage (25 ratings vs 0 for BKHA).
- Company
- Black Hawk Acquisition Corporation
- Gilead Sciences Inc.
- Price
- $12.11+0.08%
- $129.96-0.18%
- Market cap
- -
- $161.66B
- 1M return
- -0.25%
- -0.98%
- 1Y return
- +13.82%
- +13.48%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 1992
- News (4w)
- 3
- 6
- Recent ratings
- 0
- 25
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest BKHA
- Amendment: SEC Form S-4/A filed by Black Hawk Acquisition Corporation
- Black Hawk Acquisition Corporation filed SEC Form 8-K: Other Events
- SEC Form 10-Q filed by Black Hawk Acquisition Corporation
- Amendment: SEC Form S-4/A filed by Black Hawk Acquisition Corporation
- Amendment: SEC Form S-4/A filed by Black Hawk Acquisition Corporation
- Black Hawk Acquisition Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Amendment: SEC Form S-4/A filed by Black Hawk Acquisition Corporation
- Amendment: SEC Form 10-K/A filed by Black Hawk Acquisition Corporation
- SEC Form 10-Q filed by Black Hawk Acquisition Corporation
- SEC Form NT 10-Q filed by Black Hawk Acquisition Corporation
Latest GILD
- FDA Approval for VEKLURY issued to GILEAD SCIENCES INC
- CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
- Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
- Gilead Sciences downgraded by Leerink Partners with a new price target
- Chief Financial Officer Dickinson Andrew D sold $389,777 worth of shares (3,000 units at $129.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 168,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $389,758 worth of shares (3,000 units at $129.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 121,234 units (SEC Form 4)
- Gilead Sciences upgraded by HSBC Securities with a new price target
- Chairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market